Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 41 points (0.2%) at 17,740 as of Thursday, April 2, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,979 issues advancing vs. 983 declining with 171 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.3%. Top gainers within the sector include

Universal Health Services

(

UHS

), up 2.4%,

Teva Pharmaceutical Industries

(

TEVA

), up 2.1%,

Sanofi

(

SNY

), up 2.0%,

Agilent Technologies

(

A

), up 1.2% and

Actavis

(

ACT

), up 0.8%. On the negative front, top decliners within the sector include

Quintiles Transnational Holdings

(

Q

), down 2.0%,

Shire

(

SHPG

), down 1.8% and

Amgen

(

AMGN

), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Grifols

(

GRFS

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Grifols is up $0.61 (1.8%) to $33.90 on average volume. Thus far, 327,415 shares of Grifols exchanged hands as compared to its average daily volume of 613,000 shares. The stock has ranged in price between $33.69-$34.03 after having opened the day at $33.73 as compared to the previous trading day's close of $33.29.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $11.3 billion and is part of the drugs industry. Shares are down 3.5% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Grifols a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Grifols

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, reasonable valuation levels, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Grifols Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Smith & Nephew

(

SNN

) is up $0.36 (1.1%) to $34.31 on average volume. Thus far, 248,856 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 614,100 shares. The stock has ranged in price between $34.08-$34.31 after having opened the day at $34.18 as compared to the previous trading day's close of $33.95.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $16.2 billion and is part of the health services industry. Shares are down 7.6% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Smith & Nephew

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Smith & Nephew Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Medivation

(

MDVN

) is up $2.69 (2.1%) to $128.16 on average volume. Thus far, 477,846 shares of Medivation exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $124.60-$129.47 after having opened the day at $126.95 as compared to the previous trading day's close of $125.47.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $10.1 billion and is part of the drugs industry. Shares are up 26.0% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts who rate Medivation a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Medivation

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Medivation Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null